Multimodality Therapy for N2 Non-Small Cell Lung Cancer: An Evolving Paradigm

Area of Science:

• Thoracic Oncology
• Surgical Oncology
• Medical Oncology

Background:

• N2 non-small cell lung cancer (NSCLC) management involves preoperative treatment to improve outcomes.
• Optimal preoperative strategies, including induction chemotherapy (CxT) and concurrent chemoradiation (CxRT), remain debated for resectable N2 NSCLC.
• Practice patterns vary, highlighting the need for comparative outcome data.

Purpose of the Study:

• To compare multi-institutional oncologic outcomes for N2 NSCLC treated with induction chemotherapy (CxT) versus concurrent chemoradiation (CxRT) prior to surgical resection.
• To evaluate the impact of different preoperative treatment regimens on overall survival (OS) and disease-free survival (DFS).

Main Methods:

• A collaborative retrospective study involving 4 experienced lung cancer treatment centers.
• Inclusion of patients with N2 NSCLC who underwent surgical resection after either CxT or CxRT.
• Primary outcome measures included 5-year overall survival (OS) and disease-free survival (DFS), alongside recurrence rates and patterns.

Main Results:

• Analysis of 822 patients (CxT=662, CxRT=160) showed no significant differences in 5-year OS (39.9% vs 42.9%) or DFS (28.7% vs 29.8%).
• Recurrence rates (46.8% vs 51.6%) and patterns (local and distant) were not significantly different between the CxT and CxRT groups.
• No differences in perioperative mortality were observed. Subgroup analysis of patients with invasive mediastinal staging also revealed no significant differences in OS or DFS.

Conclusions:

• Both induction chemotherapy (CxT) and concurrent chemoradiation (CxRT) demonstrate equivalent oncologic outcomes for resectable N2 NSCLC.
• These preoperative strategies offer comparable survival and recurrence profiles, exceeding historical control expectations.
• Future research should investigate the role of immunotherapy in combination with these established treatments for N2 NSCLC.